Title Page

Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics

Olena Anoshchenko, Bhagwat Prasad, Naveen K. Neradugomma, Joanne Wang, Qingcheng Mao and

Jashvant D. Unadkat

Department of Pharmaceutics, University of Washington, Seattle, WA

1

Running Title Page

Abundance of transporters in human placentae

b) **Corresponding author:**

Dr. Jashvant D. Unadkat
Department of Pharmaceutics University of Washington
Box 357610
Seattle, WA 98195
Telephone: 206-543-9434
Fax: 206-543-3204
E-mail: jash@u.washington.edu

d) **Abbreviations used:**

%CV: percent coefficient of variation; ACOG: The American College of Obstetricians and

Gynecologists; ALP: Alkaline Phosphatase; BCA: bicinchoninic acid; BCRP: breast cancer resistance

protein; $CL_{invitro}$: *In Vitro* clearance; CL_{invivo}: *In Vivo* clearance; DDI: drug-drug interaction; DHEA-S:

dehydroepiandrosterone; HIV; ELISA: Enzyme Linked Immunosorbent Assay; F_t: fraction transported;

GA: gestational age; GW: gestational week; HEPES: N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic

Acid; HIV: human immunodeficiency virus; HPLC: high-performance liquid chromatography; IVIVE: in

vitro to in vivo extrapolation; K_m: Michaelis-Menten Constant; LC-MS/MS: Liquid Chromatography

Tandem Mass Specrometry; LLOQ: Lower Limit of Quantification; MP: maternal plasma; mRNA:

2

Messenger Ribonucleic Acid; Na$^+$/K$^+$-ATPase : Sodium/potassium -ATPase; NET: Norepinephrine

transporter; OAT4: Organic anion transporter 4; OATP2B1: Organic anion-transporting polypeptide;

OCT3: Organic cation transporter 3; m-f PBPK model: maternal-fetal physiologically-based

pharmacokinetic model; P-gp: P-glycoprotein; PK: pharmacokinetics; SD: standard deviation; SERT:

Serotonin transporter; T1: 1st trimester, T2: 2nd trimester; UPLC: Ultra-performance liquid chromatography;

UV: umbilical vein; UWBDRL: University of Washington Birth Defect Research Laboratory; V$_{max}$:

maximum velocity of reaction.

Abstract

Some women take medication during pregnancy to address a variety of clinical conditions. Due to ethical and logistical concerns, it is impossible to determine fetal drug exposure, and therefore fetal risk during pregnancy. Hence alternative approaches need to be developed to predict maternal-fetal drug exposure throughout pregnancy. To do so, we previously developed and verified a maternal-fetal **P**hysiologically **B**ased **P**harmaco**k**inetic (m-f-PBPK) model, which can predict fetal exposure to drugs that passively cross the placenta. However, many drugs are actively transported by the placenta (e.g. HIV protease inhibitors). In order to extend our m-f-PBPK model to these actively transported drugs, we determined the gestational-age dependent changes in the protein abundance of placental transporters. Total cellular membrane fractions from first trimester (T1, n=15), second trimester (T2, n=19) and term (n=15) human placentae, obtained from uncomplicated pregnancies, were isolated by ultracentrifugation. Transporter protein abundance was determined by targeted quantitative proteomics using LC-MS/MS. We observed that BCRP and P-gp abundance significantly decreased from T1 to term by 55% and 69%, respectively (per gram of tissue). OATP2B1 abundance significantly decreased from T1 to T2 by 32%. In contrast, OCT3 and OAT4 abundance significantly increased with gestational age (2-fold from T1 to term, 1.6-fold from T2 to term). SERT and NET did not change with gestational age. The abundance of BSEP, MRP1-5, NTCP, OATP1B1, OATP1B3, OCTN1-2, CNT1-3, ENT2, and MATE1 could not be quantified. These data can be incorporated into our m-f-PBPK to predict fetal exposure to drugs which are actively transported across the placenta.

Significance Statement

We quantified the protein abundance of key placental uptake and efflux transporters (OCT3, P-gp, BCRP) across gestational ages (T1, T2 and term) using quantitative targeted proteomics. We observed that the protein abundance of P-gp and BCRP decreased, while that of OCT3 increased with gestational age. Incorporating the protein abundance determined in this study into m-f PBPK model can help us better predict fetal drug exposure to substrates of these transporters.

Introduction

To date, approximately 40-80% of women take drugs during pregnancy and about 50% take at least one drug in the first trimester (Scaffidi, Mol, & Keelan, 2017). Pregnant women take drugs for a variety of reasons including to treat preexisting disease (e.g. depression, epilepsy), pregnancy-induced conditions (e.g. gestational diabetes and hypertension), prevent vertical transmission of infectious agents (e.g. HIV, malaria) or treat fetal conditions such as poorly developed lungs due to preterm birth (Sheffield et al., 2014).

Despite the striking prevalence of drug use during pregnancy, there is little information on the extent of maternal-fetal drug exposure throughout pregnancy. When a pregnant woman takes a drug, the fetus is de-facto exposed to the drug even if s/he is not the target for drug therapy. Fetal drug exposure, and therefore fetal risks, are driven by maternal drug exposure, placental transporters/metabolism and fetal metabolism (Zhang et al., 2017). Physiological and drug disposition changes throughout pregnancy result in time-dependent changes in maternal drug exposure (Anderson, 2005; Tasnif, Morado, & Hebert, 2016). In addition, the placenta is richly endowed with efflux transporters such as P-glycoprotein (P-gp, ABCB1)/Breast Cancer Resistance Protein (BCRP, ABCG2) (Han, Gao, & Mao, 2018; Mathias, Hitti, & Unadkat, 2005) as well as influx transporters such as organic anion transporter 4 (OAT4)/norepinephrine transporter (NET) (**Figure 1**) (Vahakangas & Myllynen, 2009). The abundance of these placental transporters may change as pregnancy proceeds (Mathias et al., 2005). Consequently, pregnancy is a dynamic process whereby maternal-fetal drug exposure changes in a time-dependent manner. Thus, for optimum therapy of the pregnant woman and to minimize fetal risk, the challenge is to measure or predict maternal-fetal drug exposure throughout pregnancy.

6

While fetal drug exposure can be determined by sampling cord blood (umbilical vein, UV) only at the time of delivery, such sampling is not possible earlier in gestation (Scaffidi et al., 2017). Also, sampling UV blood at term provides only a snapshot of fetal blood drug concentration at a given time and does not provide information on fetal drug exposure (i.e. fetal plasma/blood AUC)(Zhang et al., 2017). Moreover, even though pharmacokinetic studies of a drug can theoretically be conducted in pregnant women throughout gestation, such studies pose considerable logistical and ethical challenges. Thus, alternative methods need to be developed to predict (rather than determine) maternal-fetal drug exposure throughout pregnancy. To do so, we have developed and verified a maternal-fetal **P**hysiologically **B**ased **P**harmaco**k**inetic (m-f-PBPK) model which can predict time-dependent changes in maternal-fetal exposure to drugs metabolized by CYP enzyme and cross the placenta by passive diffusion (Zhang & Unadkat, 2017). However, many drugs are transported at the blood-placental barrier which is made of the syncytiotrophoblast layer of the placental villi (Enders & Blankenship, 1999; Joshi et al., 2016; Myllynen, Pasanen, & Pelkonen, 2005). In order to extend our m-f-PBPK model to predict maternal-fetal exposure to drugs that are transported into or out of the placenta, we determined the gestational-age dependent changes in the abundance of placental transporters by targeted quantitative proteomics using LC-MS/MS.

Materials and Method

Chemicals and Reagents. Homogenization buffer reagents and the protease inhibitor cocktail, Pefabloc SC, were purchased from Sigma-Aldrich (St. Louis, MO) and Roche, Basel, Switzerland. Omni Bead Ruptor Homogenizer, 7 mL soft tissue tubes and metal beads for homogenization were purchased from Omni International (Kennesaw, GA). Bicinchoninic acid (BCA) assay kit, dithiothreitol, iodoacetamide, sequencing grade trypsin were obtained from Pierce Biotechnology (Rockford, IL). Isotope labeled heavy internal standard peptides were obtained from Thermo Fischer Scientific (Rockford, IL) and corresponding unlabeled surrogate peptides were purchased from New England Peptide (Gardner, MA) (**Table S1**). High-performance liquid chromatography (HPLC)-grade acetonitrile, methanol, chloroform, formic acid and ammonium bicarbonate were obtained from Thermo Fischer Scientific (Fair Lawn, NJ). Sodium deoxycholate (98% purity) was purchased from MP Biomedicals (Santa Ana, CA).

Procurement of human placental tissue samples. Collection of placentae from uncomplicated pregnancies was approved and classified as nonhuman subject research by the Institutional Review Board of the University of Washington. Placentae were classified into three gestational age (GA) groups (mean±SD): 1st trimester (T1: 63.1±10.8 days, n=15), 2nd trimester (T2: 117±19.6 days, n=19) and term (n=15) (**Table 1** and **S3**). To be consistent with the definition of gestational age used by The American College of Obstetricians and Gynecologists (ACOG), T1 and T2 gestational ages were expressed based on the last menstrual period. These ages were determined by adding 14 days to the age based on fetal foot size. Gestational age of term placentae was not available. T1 and T2 placentae were obtained from University of Washington Birth Defect Research Laboratory (UWBDRL). Term placentae were obtained from the Labor

8

and Delivery Unit of the University of Washington. After collection, tissues were immediately snap frozen and stored at -80°C.

Total membrane preparation and quantitative targeted proteomics. Total membranes from human placentae were isolated by means of differential centrifugation (**Figure S1)**. Briefly, frozen tissue was thawed, washed, blotted, weighed and approximately 1.5-2 g was homogenized in Omni Bead Ruptor Homogenizer. Aqueous buffer containing 250mM sucrose, 100 mM KNO_3, 0.2 mM $CaCl_2$, 10mM HEPES, 10 mM Tris, pH7.4 was used for homogenization. Protease inhibitor cocktail Pefabloc SC (Roche, Basel, Switzerland) was used to prevent protein degradation. The homogenates were then centrifuged for 30 min at 10,000g at 4°C in Optima L-90K Ultracentrifuge (Beckman Coulter, Brea, CA) to generate S9 fractions which were immediately centrifuged at for 1 h at 125,000g at 4°C to generate cytosolic and total membrane fractions (i.e. microsomal, apical and basal plasma membranes combined). An aliquot of homogenate and membrane fractions were vesiculated through a 6-guage needle (to resuspend the sample) and diluted to working concentration of 2 mg of total protein/mL as quantified by Pierce BCA assay.

To quantify the membrane proteins by targeted proteomics, total proteins in the homogenate and membrane fractions were reduced, denatured, alkylated and concentrated, and digested by trypsin as described previously (Vertommen, Panis, Swennen, & Carpentier, 2010; Wang et al., 2005). All samples were digested in triplicates after addition of Bovine Serum Albumin (BSA, 4 µg/mL). Digestion of BSA was used to correct for any variability in digestion efficiency. Heavy-labeled internal standard of each peptide was added at the end of the trypsin digestion process. Surrogate peptides were quantified on AB Sciex Triple Quad 6500 tandem mass spectrometer coupled with Waters Acquity UPLC system (Waters, Hertfordshire, UK) (**Figure S1, Tables S1**

and S2). Calibration curve for surrogate peptide quantification consisted of Buffer A spiked with known quantities of synthetic light peptides.

To assess inter-day variability in protein abundance, membrane fractions were prepared on three different days from site 1 of T2 placentae (n=3). To assess if protein abundance was site-dependent, membrane fractions from three different sites were prepared on the same day from these T2 placentae (n=3). Only second trimester placentae were used for these analyses as the umbilical cord placement and morphology was visible for only these placentae (**Figure S2 (A)**).

Data Analysis and Scaling. Peak areas for 2 (and where possible 3 transitions) for each surrogate peptide of interest and labeled internal standard were integrated using the Analyst software (SCIEX). The average of these peak area ratios was then computed and protein abundance was calculated from calibration curves prepared in buffer A and analyzed as described before (Prasad et al., 2016). Quality control (QC) samples were similarly prepared in triplicate at the low (0.62 and 1.25 nmol/L), middle (10 nmol/L) and upper (40 nmol/L) range of the calibration line. Each LC-MS/MS run was considered qualified if the means of the QC samples were within 20% of the nominal values.

To account for variability in digestion efficiency, protein abundance was normalized to the maximum observed BSA digestion efficiency. In addition, to account for inter-tissue variability in membrane isolation, the enrichment of the apical membrane marker (Alkaline Phosphatase, ALP) and basal membrane marker (Na^+/K^+-ATPase) was quantified. ALP and Na^+/K^+ ATP-ase were selected as these proteins are highly abundant in the apical membrane and basal membrane respectively. Membrane marker enrichment was defined as the ratio of marker abundance in 1 mg of total membrane protein (MP) to marker abundance in 1 mg of homogenate protein (HP) (**Eq 1**). Transporters preferentially expressed in apical or basal membranes were corrected for the

10

corresponding membrane marker enrichment (dividing by the marker enrichment value) which then was scaled to abundance per g tissue as shown in Eq 2. Additionally, the resulting value per g tissue was scaled to pmol analyte per predicted weight of the whole placenta. The weight of each placenta was estimated as a function of gestational age (GA) using a method described earlier (**Eq 3**) (Abduljalil, Furness, Johnson, Rostami-Hodjegan, & Soltani, 2012). Predicted placental weight values were used due to the lack of information on the exact weight of each placenta.

Eq 1. $\textbf{\textit{Marker Enrichment (fold)}} = \dfrac{\frac{pmol\ Membrane\ marker}{mg\ MP}}{\frac{pmol\ Membrane\ marker}{mg\ HP}}$

Eq 2. $\textbf{\textit{Protein abundance}} \left(\dfrac{pmol\ protein}{g\ tissue}\right) = \dfrac{\frac{pmol\ protein}{mg\ MP}}{\textbf{\textit{Marker Enrichment (fold)}}} \times \dfrac{mg\ HP}{g\ tissue}$

Eq 3. $Placental\ weight\ (g) = \dfrac{-0.0122*GA^3 + 0.9149*GA^2 - 0.716*GA}{1.048}$

Abundance values for OATP2B1 in several T2 samples were below the lower limit of quantification (LLOQ) as defined by LC-MS/MS signal less than 5-times background noise. Such values were conservatively assigned the value of LLOQ. Data were analyzed by non-parametric Kruskal-Wallis and Dunn's multiple comparison test in GraphPad Prism 7 with statistical significance of $p<0.05$. Site-dependent and inter-day variability data was analyzed by Kruskal-Wallis test with Dunns's multiple comparisons (**Figure S2**). Continuous data were analyzed by Pearson correlation and significance cut-off was defined as $R^2 \geq 0.5$ (**Table 2, Figure S5**).

Results

Interday- and Site-dependent Variability in Transporter Abundance. Transporter protein abundance in three T2 placentae was independent of the sampling site and day of preparation (**Figure S2 (B, C)**) and hence Site 1 was chosen as the sampling site for further analyses. Overall, placenta H27108 showed greater variability than other two placentae (data not shown) perhaps due to its earlier gestational age.

Total Membrane Yield, Marker Enrichment and Scaling Approach. As expected, membrane protein yield was about 3% of that in the homogenate. There was modest but significant difference in protein yields between the trimesters (**Table 1, Figure 2**). Na$^+$/K$^+$-ATPase enrichment did not change significantly between three gestational age groups. ALP enrichment was significantly different at term compared to T1 and T2 (**Table 1**). A strong correlation was observed between enrichment of ALP and Na$^+$/K$^+$-ATPase within each preparation (R^2>0.63, p<0.05, data not shown), confirming the utility of these markers in addressing membrane loss during preparation. Hence, we incorporated membrane marker enrichment values into our scaling approach (**Eq 1-3**) using ALP for transporters expressed on the apical membrane and Na$^+$/K$^+$-ATPase for transporters expressed on the basal membrane of the syncytiotrophoblast.

Abundance of apical and basal membrane transporters in human placentae of various gestational ages. Of the four apical membrane transporters, BCRP and P-gp showed gestational age-dependent decrease in protein abundance (pmol of analyte per gram of tissue) between T1 and term (55% and 69% respectively) and between T2 and term (42% and 52% respectively (**Figure 3, Table S4**). Neither SERT nor NET showed significant change in protein abundance with gestation. Of the three basal membrane transporters, OCT3 and OAT4 showed respectively 2-fold (between T1 and term) and 1.6-fold (between T2 and term) increase in protein abundance.

12

OATP2B1 showed significant (32%) decrease in protein abundance between T1 and T2 (**Figure 3, Table S4**). OATP2B1 was below LLOQ (0.46 nmol/L) in five T2 samples and hence these samples were assigned the value of LLOQ. When the values were scaled to the predicted size of the whole placenta, all proteins showed drastic increase in abundance with gestational age (**Figure S3(B)**). In addition to the above proteins, the remaining transporters targeted for quantification were below the LLOQ (5-fold signal-to-noise ratio) (**Figure 1, Table S1**).

Transporters Abundance at Three Gestational Ages. When abundances of all proteins across the three gestational age groups were compared (**Figure 4**), term placentae looked notably distinct from T1 and T2. When relative transporter protein abundance was compared (**Figure 4**, pie charts), the decrease in apical membrane transporters (black bars: from 55% in T1 to 33% at term) and increase in basal membrane transporters (grey bars: from 45% in T1 to 67% at term) was observed.

Protein-Protein Correlations of Placental Transporters. Multiple pairs of transporters showed significant protein-protein correlation (Pearson correlation with p<0.05) (**Table 2, Figure S5**). Strong correlations (defined as $R^2>0.5$) were observed between BCRP and P-gp ($R^2=0.78$), BCRP and SERT ($R^2=0.62$), P-gp and SERT ($R^2=0.63$), and OAT4 and OATP2B1 ($R^2=0.53$).

13

Discussion

Although placental transporter abundance has been previously quantified by us (Mathias et al., 2005) and others (Gil, Saura, Forestier, & Farinotti, 2005; Meyer zu Schwabedissen et al., 2006; Sun et al., 2006), these studies have used either Western Blotting/ELISA to quantify the transporters or qPCR to quantify transporter mRNA expression (Nishimura & Naito, 2005). Western Blot is inherently semi-quantitative and cannot be used to compare the abundance of multiple transporters without the availability of protein standards. mRNA abundance does not always correspond to protein abundance and cannot be used for PBPK modeling and simulation. To address the shortcomings of previous studies, we incorporated several unique features in the study presented here. First, we utilized the state-of-the art targeted quantitative proteomics method to quantify the abundance of multiple transporters, a method that does not depend on the availability of protein standards. These transporters were chosen based on previously published gene expression data (mRNA or protein) indicating that they are present in the human placenta (Mathias et al., 2005; Gil, Saura, Forestier, & Farinotti, 2005; Meyer zu Schwabedissen et al., 2006; Sun et al., 2006; Nishimura & Naito, 2005). Second, we quantified the abundance of transporters across multiple gestational ages from placentae obtained from uncomplicated pregnancies. Third, we extended the transporters quantified to those not previously studied (e.g. SERT, NET). Fourth, we utilized a greater number of placentae in each gestational age (n=15) than prior studies. Fifth, we determined if the abundance of the transporters in the placentae was sample-site dependent. Sixth, we corrected the inter-tissue variability in membrane isolation by utilizing enrichment of validated membrane markers, ALP and Na^+/K^+-ATPase.

We did not observe any significant differences when preparations were made on different days or sampled from different sites (**Figure S2**). Lack of inter-day variability indicated our

14

technical consistency in preparation methodology and lack of site-dependent variability implied homogeneous distribution of transporters throughout placenta and was also observed before in term placentae (Memon et al., 2014). Due to this lack of variability, we chose to prepare membrane fractions using tissue obtained from site 1 (**Figure S2**) for all the placenta samples.

We observed a 3-4 fold enrichment of membrane markers in all the preparations. Membrane marker enrichment value was incorporated into the scaling strategy to control for the variability in membrane loss between preparations. ALP and Na^+/K^+-ATPase were chosen as highly abundant markers detectable in both homogenate and membrane fractions. Two separate markers were chosen due to the possible differences in enrichment of apical or basal membranes. Overall, the fold-enrichment values for both markers were comparable for each gestational age except for higher ALP enrichment values at term (**Table 1**). Both enrichment values were relatively low compared with those reported in the literature (separate isolation of apical and basal membranes) (Illsley, Wang, Gray, Sellers, & Jacobs, 1990; Jimenez, Henriquez, Llanos, & Riquelme, 2004; Kelley, Smith, & King, 1983). The reason for this difference is unknown but could be due to greater contamination from other membranes during our preparation. Nonetheless, the low enrichment values did not detract from our ability to quantify the most abundant and important xenobiotic transporters (i.e., P-gp, BCRP, and OCT3) while the abundance of other transporters was below limits of detection (i.e., MRP1-5, OATP1B1/3, MATE1, OCTN1/2, CNT2/3, BSEP, and NTCP) (**Figure 1, Table S1**).

We found the most pronounced differences with gestational age in abundance of BCRP, P-gp and OCT3 while that of OAT4 and OATP2B1 proteins was less affected (**Figure 3**). This differential gestational-age transporter abundance indicates that the observed changes are not an artifact of our method. The mechanistic basis of this differential effect remains to be elucidated.

15

Teleologically, increased abundance of efflux transporters per gram of tissue could be a mechanism to protect the fetus from exposure to xenobiotics. In addition, these results are consistent with previous studies conducted by us and others on P-gp (Gil et al., 2005; Sun et al., 2006), BCRP (Meyer zu Schwabedissen et al., 2006) and OCT3 (Lee et al., 2013). More modest changes in protein abundance for OAT4 and OATP2B1 as well as the lack of significant changes in abundance of SERT and NET are described here for the first time. Additionally, current findings agree with the previous conclusion that the placenta is the highest BCRP-expressing organ (compared to the kidney and liver) and show that placental P-gp protein abundance is similar to that in the liver (**Figure S4**).

The impact of these transporter abundances on fetal distribution of drugs can now be predicted using PBPK modeling and simulation. To do so, the abundance of the transporters in the entire organ is needed. When scaled to the whole organ, a consistent gestational age-dependent increase in abundance of all 7 proteins was observed (**Figure S3 (B)**). This finding is due to the dramatic increase in placental weight (hundreds of fold) with gestation (**Eq 3**) in comparison to modest changes (2-3 fold) in protein abundance per gram of tissue. Hence, placental weight becomes the major determinant for the differences observed in the whole organ.

Our quantification results captured some elements of placentogenesis, a very dynamic and multifaceted process (Abduljalil et al., 2012; Burton & Fowden, 2015). The pattern of placental transporter protein abundance was similar between T1 and T2 but less so between T1/T2 and term (**Figure 4**). Such observations can be explained by the T1 and T2 placentae being closer in gestational age than Term placentae (**Table 1**) and hence more similar in developmental processes. Additionally, induction of parturition-responsive genes can alter placental gene expression as the organ reaches term (Peng et al., 2011). Hence, at earlier

16

gestational ages (T1 and T2) fetal drug exposure to transporter substrates may be more similar than at term.

The observed strong correlation between pairs of protein abundances (**Table 2, Figure S5**) may indicate the involvement of common regulatory mechanisms (e.g. by the same nuclear receptor) or possibly protein-protein interactions as reported between OATP1B3 and OCT1 in human hepatocytes (Shoop, Ruggiero, Zhang, & Hagenbuch, 2015).

Our approach to transporter quantification has several limitations. We assumed that all measured transporter proteins are active and localized to the membrane indicated in Fig.1 rather than internalized or present in cells other than the syncytiotrophoblast layer (Joshi et al., 2016; Vahakangas & Myllynen, 2009). Since the enrichment values for both ALP and Na^+/K^+-ATPase were similar, misclassification as to which membrane (apical vs. basal) the transporter is localized to will not have a large impact on the quantification of the transporters and eventual use of these values in IVIVE. Although methods are available to separate the apical from the basal membrane, such methods do not yield complete purification of each membrane (Jimenez et al., 2004). Therefore, we believe that our approach of using a membrane marker is superior to experimentally attempt to separate the apical from the basal membrane. The use of biotinylation assay can potentially address localization in *in vitro* systems (Kumar, Nguyen, Toth, Juhasz, & Unadkat, 2017), although such estimation in *ex vivo* tissue has not been evaluated. Further, in addition to syncytiotrophoblast, some transporters (e.g. OCT3, BCRP) have been reported to be present on other placental cell types such as the endothelial cells (Joshi et al., 2016; Lee et al., 2018). Thus, our approach may lead to an overestimation of total transporter proteins at the plasma membrane of syncytiotrophoblast.

17

Collectively, these data can be used to populate a maternal-fetal PBPK model to predict fetal exposure to xenobiotic transporter substrates at various gestational ages. Failing to account for placental transporter abundance changes (e.g., P-gp) may lead to biased estimates of fetal exposure to transporter substrates and therefore fetal drug toxicity and efficacy (for drugs where fetus is a therapeutic target, e.g. antenatal corticosteroids or HIV drugs). To predict fetal drug exposure these data should be married with drug transport kinetics (i.e., K_m and V_{max}) determined *in vitro*, where the *in vitro* V_{max} can be extrapolated to that *in vivo* using the proteomics data presented here. Additionally, this transporter abundance can also help estimate the fraction transported (f_t), *in vivo*, by a given transporter. Estimate of f_t will also aid in prediction of placental drug-drug interactions that can modulate fetal drug exposure. This is especially important because when monitored from maternal plasma, perpetrator-driven inhibition of drug efflux (e.g., P-gp) can go undetected in maternal plasma while considerably modulating fetal drug exposure and therefore fetal toxicity or efficacy (Patilea-Vrana & Unadkat, 2016). Collectively, gestational age-dependent abundance of transporters in the placenta is valuable in predicting fetal drug exposure and therefore fetal efficacy and toxicity associated with drug administration during pregnancy (Zhang & Unadkat, 2017).

Acknowledgements

19

Authorship Contributions

Participated in research design: Anoshchenko, Prasad, Unadkat

Conducted experiments: Anoshchenko

Contributed new reagents or analytic tools: Mao, Wang

Performed data analysis: Anoshchenko

Wrote or contributed to the writing of the manuscript: Anoshchenko, Prasad, Neradugomma, Wang, Mao, Unadkat

20

References

Abduljalil, K., Furness, P., Johnson, T. N., Rostami-Hodjegan, A., & Soltani, H. (2012). Anatomical, physiological
and metabolic changes with gestational age during normal pregnancy: a database for parameters required in
physiologically based pharmacokinetic modelling. *Clin Pharmacokinet, 51*(6), 365-396.
doi:10.2165/11597440-000000000-00000

Atkinson, D. E., Sibley, C. P., Fairbairn, L. J., & Greenwood, S. L. (2006). MDR1 P-gp expression and activity in
intact human placental tissue; upregulation by retroviral transduction. *Placenta, 27*(6-7), 707-714.
doi:10.1016/j.placenta.2005.06.008

Balkovetz, D. F., Tiruppathi, C., Leibach, F. H., Mahesh, V. B., & Ganapathy, V. (1989). Evidence for an
imipramine-sensitive serotonin transporter in human placental brush-border membranes. *J Biol Chem,
264*(4), 2195-2198.

Blanco-Castaneda, R., Galaviz-Hernandez, C., Souto, P. C. S., Lima, V. V., Giachini, F. R., Escudero, C., . . . Sosa-
Macias, M. (2020). The role of xenobiotic-metabolizing enzymes in the placenta: a growing research field.
Expert Rev Clin Pharmacol, 1-17. doi:10.1080/17512433.2020.1733412

Bottalico, B., Larsson, I., Brodszki, J., Hernandez-Andrade, E., Casslen, B., Marsal, K., & Hansson, S. R. (2004).
Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter
(VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and
normotensive pregnancies. *Placenta, 25*(6), 518-529. doi:10.1016/j.placenta.2003.10.017

Burton, G. J., & Fowden, A. L. (2015). The placenta: a multifaceted, transient organ. *Philos Trans R Soc Lond B
Biol Sci, 370*(1663), 20140066. doi:10.1098/rstb.2014.0066

Enders, A. C., & Blankenship, T. N. (1999). Comparative placental structure. *Adv Drug Deliv Rev, 38*(1), 3-15.

Gil, S., Saura, R., Forestier, F., & Farinotti, R. (2005). P-glycoprotein expression of the human placenta during pregnancy. *Placenta, 26*(2-3), 268-270. doi:10.1016/j.placenta.2004.05.013

Han, L. W., Gao, C., & Mao, Q. (2018). An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus. *Expert Opin Drug Metab Toxicol, 14*(8), 817-829. doi:10.1080/17425255.2018.1499726

Illsley, N. P., Wang, Z. Q., Gray, A., Sellers, M. C., & Jacobs, M. M. (1990). Simultaneous preparation of paired, syncytial, microvillous and basal membranes from human placenta. *Biochim Biophys Acta, 1029*(2), 218-226.

Jimenez, V., Henriquez, M., Llanos, P., & Riquelme, G. (2004). Isolation and purification of human placental plasma membranes from normal and pre-eclamptic pregnancies. a comparative study. *Placenta, 25*(5), 422-437. doi:10.1016/j.placenta.2003.10.013

Joshi, A. A., Vaidya, S. S., St-Pierre, M. V., Mikheev, A. M., Desino, K. E., Nyandege, A. N., . . . Gerk, P. M. (2016). Placental ABC Transporters: Biological Impact and Pharmaceutical Significance. *Pharm Res, 33*(12), 2847-2878. doi:10.1007/s11095-016-2028-8

Kelley, L. K., Smith, C. H., & King, B. F. (1983). Isolation and partial characterization of the basal cell membrane of human placental trophoblast. *Biochim Biophys Acta, 734*(1), 91-98.

Kumar, V., Nguyen, T. B., Toth, B., Juhasz, V., & Unadkat, J. D. (2017). Optimization and Application of a Biotinylation Method for Quantification of Plasma Membrane Expression of Transporters in Cells. *AAPS J, 19*(5), 1377-1386. doi:10.1208/s12248-017-0121-5

Lee, N., Hebert, M. F., Prasad, B., Easterling, T. R., Kelly, E. J., Unadkat, J. D., & Wang, J. (2013). Effect of gestational age on mRNA and protein expression of polyspecific organic cation transporters during pregnancy. *Drug Metab Dispos, 41*(12), 2225-2232. doi:10.1124/dmd.113.054072

Lee, N., Hebert, M. F., Wagner, D. J., Easterling, T. R., Liang, C. J., Rice, K., & Wang, J. (2018). Organic Cation Transporter 3 Facilitates Fetal Exposure to Metformin during Pregnancy. *Mol Pharmacol, 94*(4), 1125-1131. doi:10.1124/mol.118.112482

Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., . . . Schellens, J. H. (2001). Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res, 61*(8), 3458-3464.

Mathias, A. A., Hitti, J., & Unadkat, J. D. (2005). P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. *Am J Physiol Regul Integr Comp Physiol, 289*(4), R963-969. doi:10.1152/ajpregu.00173.2005

Memon, N., Bircsak, K. M., Archer, F., Gibson, C. J., Ohman-Strickland, P., Weinberger, B. I., . . . Aleksunes, L. M. (2014). Regional expression of the BCRP/ABCG2 transporter in term human placentas. *Reprod Toxicol, 43*, 72-77. doi:10.1016/j.reprotox.2013.11.003

Meyer zu Schwabedissen, H. E., Grube, M., Dreisbach, A., Jedlitschky, G., Meissner, K., Linnemann, K., . . . Kroemer, H. K. (2006). Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). *Drug Metab Dispos, 34*(4), 524-533. doi:10.1124/dmd.105.007591

Myllynen, P., Immonen, E., Kummu, M., & Vahakangas, K. (2009). Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. *Expert Opin Drug Metab Toxicol, 5*(12), 1483-1499. doi:10.1517/17425250903304049

Myllynen, P., Pasanen, M., & Pelkonen, O. (2005). Human placenta: a human organ for developmental toxicology research and biomonitoring. *Placenta, 26*(5), 361-371. doi:10.1016/j.placenta.2004.09.006

Nishimura, M., & Naito, S. (2005). Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. *Drug Metab Pharmacokinet, 20*(6), 452-477.

Patilea-Vrana, G., & Unadkat, J. D. (2016). Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model. *Clin Pharmacol Ther, 100*(5), 413-418. doi:10.1002/cpt.437

Peng, H. H., Kao, C. C., Chang, S. D., Chao, A. S., Chang, Y. L., Wang, C. N., . . . Wang, H. S. (2011). The effects of labor on differential gene expression in parturient women, placentas, and fetuses at term pregnancy. *Kaohsiung J Med Sci, 27*(11), 494-502. doi:10.1016/j.kjms.2011.06.012

Prasad, B., Gaedigk, A., Vrana, M., Gaedigk, R., Leeder, J. S., Salphati, L., . . . Unadkat, J. D. (2016). Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics. *Clin Pharmacol Ther, 100*(4), 362-370. doi:10.1002/cpt.409

Scaffidi, J., Mol, B. W., & Keelan, J. A. (2017). The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy. *BJOG, 124*(1), 132-140. doi:10.1111/1471-0528.14151

Sheffield, J. S., Siegel, D., Mirochnick, M., Heine, R. P., Nguyen, C., Bergman, K. L., . . . Nesin, M. (2014). Designing drug trials: considerations for pregnant women. *Clin Infect Dis, 59 Suppl 7*, S437-444. doi:10.1093/cid/ciu709

Shoop, J., Ruggiero, M., Zhang, Y., & Hagenbuch, B. (2015). Protein-Protein Interactions Between Organic Anion Transporting Polypeptide 1B3 (OATP1B3) and Organic Cation Transporter 1 (OCT1). *The FASEB Journal, 29*(1_supplement), 939.936. doi:10.1096/fasebj.29.1_supplement.939.6

Sun, M., Kingdom, J., Baczyk, D., Lye, S. J., Matthews, S. G., & Gibb, W. (2006). Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. *Placenta, 27*(6-7), 602-609. doi:10.1016/j.placenta.2005.05.007

Ugele, B., Bahn, A., & Rex-Haffner, M. (2008). Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta. *J Steroid Biochem Mol Biol, 111*(1-2), 1-6. doi:10.1016/j.jsbmb.2008.04.001

Vahakangas, K., & Myllynen, P. (2009). Drug transporters in the human blood-placental barrier. *Br J Pharmacol, 158*(3), 665-678. doi:10.1111/j.1476-5381.2009.00336.x

Vertommen, A., Panis, B., Swennen, R., & Carpentier, S. C. (2010). Evaluation of chloroform/methanol extraction to facilitate the study of membrane proteins of non-model plants. *Planta, 231*(5), 1113-1125. doi:10.1007/s00425-010-1121-1

Wang, H., Qian, W. J., Mottaz, H. M., Clauss, T. R., Anderson, D. J., Moore, R. J., . . . Smith, R. D. (2005). Development and evaluation of a micro- and nanoscale proteomic sample preparation method. *J Proteome Res, 4*(6), 2397-2403. doi:10.1021/pr050160f

Zhang, Z., Imperial, M. Z., Patilea-Vrana, G. I., Wedagedera, J., Gaohua, L., & Unadkat, J. D. (2017). Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses. *Drug Metab Dispos*. doi:10.1124/dmd.117.075192

25

Zhang, Z., & Unadkat, J. D. (2017). Verification of a Maternal-Fetal Physiologically Based Pharmacokinetic Model

for Passive Placental Permeability Drugs. *Drug Metab Dispos*. doi:10.1124/dmd.116.073957

Footnotes

Legends for Figures

Figure 1. Transporters, their proposed localization and directionality of transport in the syncytiotrophoblast of the human placenta. Transporters and membrane markers that were successfully quantified are shown in green (basal membrane proteins) and blue (apical membrane proteins) (success criterion: LLOQ 5-fold signal-to-noise ratio) while the ones targeted, but not quantifiable (below LLOQ), are shown in grey. Most abundant drug metabolizing enzymes that are present in the placenta but were not attempted to quantify are indicated in the red oval (Blanco-Castaneda et al., 2020)**.** The key studies and review articles informing membrane localization of the transporters were: P-gp (Atkinson, Sibley, Fairbairn, & Greenwood, 2006; Sun et al., 2006); BCRP (Maliepaard et al., 2001); SERT (Balkovetz, Tiruppathi, Leibach, Mahesh, & Ganapathy, 1989; Bottalico et al., 2004); NET(Bottalico et al., 2004); OCT3 (Lee et al., 2018); OAT4 (Ugele, Bahn, & Rex-Haffner, 2008) and OATP2B1 (Ugele et al., 2008); key review articles (Han et al., 2018; Joshi et al., 2016; Myllynen, Immonen, Kummu, & Vahakangas, 2009; Vahakangas & Myllynen, 2009)**.**

Figure 2. Total protein yield in homogenate (HP) and total membranes (MP) isolated from T1, T2 and Term placentae. Lines denote mean and standard deviations (T1 n=15; T2 n=19; Term n=15). Significant differences by Kruskal-Wallis Test (with Dunn's multiple comparisons) are indicated. Mean values are also presented in **Table S4**. *T1 – 1ˢᵗ trimester, T2 – 2ⁿᵈ trimester*.

Figure 3. Protein abundance of apical and basal membrane transporters in human placentae of three gestational ages (pmol/g tissue). Abundance of BCRP was 55% lower at term than in T1 and 42% lower at term than in T2 (p<0.05). Abundance of P-gp was 69% lower at term than in T1 and 52% lower at term than in T2 (p<0.05). Abundance of OCT3 was 2-fold

higher at Term than in T1. Abundance of OAT4 was 1.6-fold higher at term than in T2. Abundance of OATP2B1 was 32% lower in T2 than in T1. Neither SERT nor NET showed significant change in protein abundance with gestational age. Dots are measured values, lines are mean and standard deviations (T1, n=15; T2, n=19; Term, n=15); only significant differences (Kruskal-Wallis Test with Dunn's multiple comparisons) are shown except for NET, where *ns* denotes marginally insignificant difference. *T1 – 1st trimester, T2 – 2nd trimester*.

Figure 4. Protein abundance of transporters in human placentae per gram of tissue (A-C bar graphs) or as percent of the total abundance of the quantified transporters (A-C pie charts) at three gestational ages. The data show the changes in pattern of expression as pregnancy proceeds. T1 and T2 placentae show similar pattern of transporter abundance while term placentae show a distinct pattern. The change in contribution of all basal membrane transporters increased from 45/46% in T1/T2 to 67% at Term. Consequently, apical membrane transporter contribution decreased from 55/54% in T1/T2 to 33% at Term. Data shown in bar graphs are means±SD. Data were analyzed using the Kruskal-Wallis Test with Dunn's multiple comparisons. T1 – 1st trimester, T2 – 2nd trimester.

Tables

Table 1. Gestational age grouping, protein yield and membrane marker enrichment of placentae. Data shown as means ± SD. Identical symbols next to the values denote significant differences between the respective values (Kruskal-Wallis test with Dunn's multiple comparisons, $p<0.05$, T1 – 1st trimester, T2 – 2nd trimester).

	T1 **Day 1 - 98**	**T2** **Day 99 - 196**	**Term** **Day 273 - 287**
Gestational Age (days)	63.1±10.8	117±19.6	N/A
Number of Samples	15	19	15
Homogenate Total Protein yield (mg HP / g tissue)	26.6±8.5 [†]	20.1±3.0 [†,‡]	28.5±7.4 [‡]
Membrane Total Protein Yield (mg MP / g tissue)	0.8±0.4 [$]	0.7±0.3	0.5±0.2 [$]
Membrane Marker Enrichment (fold)			
Alkaline Phosphatase	3.0±1.7 [&]	2.7±1.2 [^]	4.2±1.5 [&, ^]
Na+/K+-ATPase	3.1±2.3	2.7±1.0	2.2±1.1

Table 2. Protein-protein correlation of placental transporter abundance (N=49).

Correlations with Pearson correlation of $R^2>0.5$ (black cells).

	BCRP	P-gp	SERT	NET	OAT4	OATP2B1	OCT3
BCRP							
P-gp	**0.78**						
SERT	**0.62**	**0.63**					
NET	0.10	0.11	0.34				
OAT4	0.10	0.11	0.22	0.28			
OATP2B1	0.10	0.19	0.26	0.15	**0.53**		
OCT3	0.00	0.00	0.05	0.16	0.42	0.43	

Figure 1

Figure 2

Figure 3

pmol transporter protein / g tissue

Figure 4